Largest Gene Study In Childhood IBD Finds 5 New Genes

In the largest, most comprehensive genetic analysis of childhood-onset inflammatory bowel disease (IBD), an international research team has identified five new gene regions, including one involved in a biological pathway that helps drive the painful inflammation of the digestive tract that characterizes the disease. A research team led by Hakon Hakonarson, M.D., Ph.D.

 

Ironwood And Forest Announce Positive Linaclotide Results From Two Pivotal Phase 3 Trials In Patients With Chronic Constipation

Ironwood Pharmaceuticals, Inc. and Forest Laboratories, Inc. (NYSE: FRX) today announced positive top-line results from two Phase 3 clinical trials assessing the safety and efficacy of once-daily dosing of the investigational drug linaclotide in patients with chronic constipation (CC).

 

Lexicon Announces Positive Phase 2 Results Of LX1031 In Non-Constipating Irritable Bowel Syndrome

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced that the company’s investigational new drug, LX1031, a tryptophan hydroxylase (TPH) inhibitor, demonstrated positive results in clinically important parameters for the treatment of non-constipating irritable bowel syndrome (IBS).

 

New Tool To Accelerate Discovery Of Autoimmune Disease Mechanisms And Therapies

Currently, 5 – 8% of the U.S. population is afflicted with an autoimmune disease. Many of these are chronic and require life-long care. Moreover, different autoimmune diseases aggregate within a single family, suggesting they are caused by disruptions in common biological pathways. To help researchers investigate these common pathways, The Jackson Laboratory has published Pathways to Discovery: Autoimmune Diseases (

 

Possible Link Between Inflammatory Bowel Disease Treatment And Non-Melanoma Skin Cancer

Findings from a new retrospective cohort study presented at the American College of Gastroenterology’s 74th Annual Scientific meeting in San Diego indicate that patients with Inflammatory Bowel Disease (IBD), especially those receiving the thiopurine class of medications to treat IBD, may be at risk for developing non-melanoma skin cancer (NMSC). Dr.

 

Irritable Bowel Syndrome Video

Irritable bowel syndrome, simply called as IBS, is a functional bowel disorder in which the intestines of the person affected either squeeze too hard or just not hard enough, causing food to either move too quickly or too slowly in the intestines.When you are a patient of IBS you should see this video film of Hiromi Shinya, M.D

 

Irritable Bowel Syndrome Diagnosis

Irritable bowel syndrome or IBS is a type of functional bowel disorder that affects a person’s intestines and the efficiency and normalcy of his or her bowel movement and habits.

 

Irritable Bowel Syndrome Causes

Irritable bowel syndrome is also known in gastroenterology as functional bowel disorder, spastic bowel, spastic colon, and irritable colon.

 

Irritable Bowel Syndrome

Irritable bowel syndrome or IBS is often confused by many people with inflammatory bowel disease or IBD. If you too are having trouble differentiating the two terms, which are not similar, it is important to remember vital facts about IBS.